HER-2 Mutations in Non-Small Cell Lung Cancer

dc.contributor.authorSen, Erdem
dc.contributor.authorYavas, Guler
dc.contributor.authorAta, Ozlem
dc.date.accessioned2020-03-26T19:54:08Z
dc.date.available2020-03-26T19:54:08Z
dc.date.issued2018
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractLung cancer is a heterogeneous and complex disease. Oncogenic driver mutations are critical for lung cancer development and serve as therapeutic targets. Oncogenic driver mutations are well defined in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and reactive oxygen species-1 (ROS-1) mutations. Human epidermal growth factor receptor-2 (HER-2) positivity and anti-HER-2 treatments are well studied in breast cancer. In non-small cell lung cancer (NSCLC), these treatment approaches are under investigation. In NSCLC, mutations of HER-2 are found in 2%-4% of cases. The most commonly encountered mutations are frame insertions in exon 20. There is no evident association between HER-2 amplification and HER-2 mutations. HER-2-targeted therapy needs further clinical investigations in NSCLC.en_US
dc.identifier.doi10.5350/BTDMJB.20170418063202en_US
dc.identifier.endpage325en_US
dc.identifier.issn1305-9319en_US
dc.identifier.issn1305-9327en_US
dc.identifier.issue3en_US
dc.identifier.pmid#YOKen_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage322en_US
dc.identifier.urihttps://dx.doi.org/10.5350/BTDMJB.20170418063202
dc.identifier.urihttps://hdl.handle.net/20.500.12395/36668
dc.identifier.volume14en_US
dc.identifier.wosWOS:000445436900012en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherYERKURE TANITIM & YAYINCILIK HIZMETLERI A Sen_US
dc.relation.ispartofMEDICAL JOURNAL OF BAKIRKOYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectHER-2 mutationsen_US
dc.subjectnon-small cell lung canceren_US
dc.subjectHER-2 targeted therapyen_US
dc.titleHER-2 Mutations in Non-Small Cell Lung Canceren_US
dc.typeArticleen_US

Dosyalar